| Literature DB >> 29966799 |
Luciano Mutti1, Tobias Peikert2, Bruce W S Robinson3, Arnaud Scherpereel4, Anne S Tsao5, Marc de Perrot6, Gavitt A Woodard7, David M Jablons7, Jacinta Wiens8, Fred R Hirsch9, Haining Yang10, Michele Carbone10, Anish Thomas11, Raffit Hassan12.
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics. Published by Elsevier Inc.Entities:
Keywords: Biomarkers; Chemotherapy; Immunotherapy; Malignant pleural mesothelioma; Oncology therapeutics
Mesh：
Year: 2018 PMID： 29966799 PMCID： PMC6643278 DOI： 10.1016/j.jtho.2018.06.011
Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609